肿瘤细胞治疗研究
英文原题：Carboplatin enhances lymphocyte-endothelial interactions to promote CD8(+) T cell trafficking into the ovarian tumor microenvironment.
Carboplatin enhances lymphocyte-endothelial interactions to promote CD8(+) T cell trafficking into the ovarian tumor microenvironment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些新发现提示，化疗药物除了诱导免疫原性肿瘤细胞死亡外，还可能广泛影响抗肿瘤免疫应答。
标准化疗药物，包括卡铂，具有已知的免疫原性特性。我们试图确定卡铂如何影响淋巴细胞向肿瘤部位的迁移。
利用卵巢癌小鼠模型，研究淋巴细胞 trafficking，涉及临床常用药物包括卡铂、anti-PD-1 抗体或 anti-VEGFR-2 抗体。使用活体显微镜测量淋巴细胞与肿瘤血管的黏附相互作用，用免疫组化检测淋巴细胞归巢，并随访治疗组的总生存期。
卡铂化疗深刻改变肿瘤微环境，促进淋巴细胞与肿瘤血管的黏附相互作用，并由此改善淋巴细胞的转运。在肿瘤微环境中观察到的卡铂治疗效果优于抗PD-1治疗或抗VEGFR-2治疗，这可能有助于提高卡铂治疗组的总生存期。
Standard chemotherapy agents, including carboplatin, have known immunogenic properties. We sought to determine how carboplatin may influence lymphocyte trafficking to tumor sites.
Murine models of ovarian cancer were utilized to examine lymphocyte trafficking with common clinically used agents including carboplatin, anti-PD-1 antibody, or anti-VEGFR-2 antibody. Adhesion interactions of lymphocytes with tumor vasculature were measured using intravital microscopy, lymphocyte homing with immunohistochemistry, and treatment groups followed for overall survival.
Carboplatin chemotherapy profoundly alters the tumor microenvironment to promote lymphocyte adhesive interactions with tumor vasculature and resultant improvement in lymphocyte trafficking. The measured results seen with carboplatin in the tumor microenvironment were superior to anti-PD-1 treatment or anti-VEGFR-2 which may have contributed to increased overall survival in carboplatin treated groups.
These novel findings suggest a role for chemotherapeutic agents to broadly influence anti-tumor immune responses beyond the induction of immunogenic tumor cell death.
MEMBER ACCOUNT
登录成功会直接打开下一页。
